Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer
May 29, 2018
Remote Monitoring Can Reduce Radiation-Related Symptoms in Head and Neck Cancer
May 30, 2018
Despite USPSTF Recommendations, Lung Screening Rates Low Among Heavy Smokers
May 31, 2018
Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers
June 01, 2018
Dr Leonard B. Saltz on Deciding When a Patient Should Receive NGS Testing
June 02, 2018
Promising Early Phase Results With bb2121 CAR T Treatment in Relapsed Refractory Multiple Myeloma
June 02, 2018
Dr Peter Paul Yu Discusses the Impact of Health Information Technology in Oncology
June 02, 2018
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
June 02, 2018
Currently Reading
Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine
June 02, 2018
Utilization Management in Oncology: Current Strategies and a Path Forward
June 02, 2018
Immune Checkpoint Inhibitors Improve Outcomes in Mismatch Repair Deficient CRC, but Can Induce irAEs
June 02, 2018
ZUMA-1: Response to Axi-cel at Three Months Prognostic for Remission in B-cell Lymphoma
June 03, 2018
Cetuximab With Chemoradiation Worse Than Chemoradiation Alone in Older Patients With HNSCC
June 03, 2018
Dr Michael Thompson: The Role of Precision Medicine in the Community Setting
June 03, 2018
Dr Victoria Villaflor Outlines Challenges With Pursuing Precision Medicine
June 03, 2018
Clinical Trials: Sharing the Road With Real-World Evidence
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
Nearly Half of Patients With Metastatic CSCC Respond to Cemiplimab, on Fast Track at FDA
June 04, 2018
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018

Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine

In order for precision oncology to be fruitful and to be effective, we need interoperability and we need to be able to share patient data, said James Lin Chen, MD, Ohio State University, and chair of ASCO CancerLinQ Oncology Informatics Task Force. 


In order for precision oncology to be fruitful and to be effective, we need interoperability and we need to be able to share patient data, said James Lin Chen, MD, Ohio State University, and chair of ASCO CancerLinQ Oncology Informatics Task Force. 

Transcript

How has precision medicine changed the information needs for oncologists and tumor boards?

So, I talked about 5 rights of precision medicine today: the right diagnosis, the right test that needed to be made to make a diagnosis, the right targets, the right treatment, and the right monitoring. That all goes along with this. But along these rights for the right treatment for precision medicine are the data sets that underlie it. So, you need prognostic biomarkers, diagnostic biomarkers, monitoring biomarkers.

You also need guidelines in terms of what are the appropriate tests to run in the first place. Precision medicine has really opened up the world of biomarkers to oncologists, and that is, I think, one of the big paradigm shifts.

How does health information technology play a role in obtaining the information needed to make an informed decision for a patient?

In order for precision oncology to be fruitful and to be effective, we need interoperability and we need to be able to share patient data, because the more data that we have that we can aggregate together, the better the better the quality of the predictions we can make. So, predicting for a very small set of patients is going to be prone to error, but if we have a very large set of patients, we’re going to be able to make better predictions for who might respond to therapy.

So, in the era of electronic health records, I don’t think we’re quite there yet, but there’s a lot of work that needs to be done from a harmonization standpoint, from an interoperability standpoint, as well as simply data standardization. One of the issues that came up today during the talk was that we don’t have a common nomenclature on how to capture genes or gene alterations. These standards are being developed and they’re starting to be implemented. But, they’re starting to be implemented, we’re not quite there yet from an interoperability point of view.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!